NeoGenomics (NEO): A Genomic Stock Worth Checking?

NeoGenomics Inc. (NASDAQ:NEO), founded in 2002, runs a laboratory network across the U.S., with a prime focus on cancer genetics diagnostic testing.

Keep Reading →